» Articles » PMID: 38008036

Does Bisphenol A (BPA) Participates in the Pathogenesis of Polycystic Ovary Syndrome (PCOS)?

Overview
Publisher Elsevier
Specialty General Medicine
Date 2023 Nov 26
PMID 38008036
Authors
Affiliations
Soon will be listed here.
Abstract

PCOS is an endocrine disorder characterized by chronic anovulation, hyperandrogenism, and polycystic ovaries. Its etiology is uncertain. It is debated whether BPA would be a component of the environmental factor in the etiology of PCOS. Contamination by BPA can occur from food packaging (exposure during the diet) and through skin absorption and/or inhalation. It can be transferred to the fetus via the placenta or to the infant via breast milk, and it can be found in follicular fluid, fetal serum, and amniotic fluid. The phenolic structure of BPA allows it to interact with Estrogen Receptors (ERs) through genomic signaling, in which BPA binds to nuclear ERα or Erβ, or through nongenomic signaling by binding to membrane ERs, prompting a rapid and intense response. With daily and constant exposure, BPA's tendency to bioaccumulate and its ability to activate nongenomic signaling pathways can alter women's metabolic and reproductive function, leading to hyperandrogenism, insulin resistance, obesity, atherogenic dyslipidemia, chronic inflammatory state, and anovulation and favoring PCOS. The harmful changes caused by BPA can be passed on to future generations without the need for additional exposure because of epigenetic modifications. Not only high BPA levels can produce harmful effects, but at low levels, BPA may be harmful when exposure occurs during the most vulnerable periods, such as the fetal and neonatal periods, as well as during the prepubertal age causing an early accumulation of BPA in the body. Learning how BPA participates in the pathogenesis of PCOS poses a challenge and further studies should be conducted.

Citing Articles

Mitigating Dietary Bisphenol Exposure Through the Gut Microbiota: The Role of Next-Generation Probiotics in Bacterial Detoxification.

Emanowicz P, Srednicka P, Wojcicki M, Roszko M, Juszczuk-Kubiak E Nutrients. 2024; 16(21).

PMID: 39519589 PMC: 11547510. DOI: 10.3390/nu16213757.


Which is the current knowledge on man-made endocrine- disrupting chemicals in follicular fluid? An overview of effects on ovarian function and reproductive health.

Shulhai A, Bianco V, Donini V, Esposito S, Street M Front Endocrinol (Lausanne). 2024; 15:1435121.

PMID: 39415794 PMC: 11479995. DOI: 10.3389/fendo.2024.1435121.


The Role of 11-Oxygenated Androgens and Endocrine Disruptors in Androgen Excess Disorders in Women.

Vitku J, Varausova A, Skodova T, Kolatorova L, Vosatkova M, Vcelak J Int J Mol Sci. 2024; 25(17).

PMID: 39273637 PMC: 11395667. DOI: 10.3390/ijms25179691.


Polycystic ovary syndrome: emerging stem cell therapies.

Busari K, Tulay P Rev Assoc Med Bras (1992). 2024; 70(6):e20231436.

PMID: 39045951 PMC: 11288272. DOI: 10.1590/1806-9282.20231436.


The association of CYP11A1 gene polymorphisms with the polycystic ovary syndrome patients.

Alyousif S, Ozbakir B, Ozay A, Tulay P Rev Assoc Med Bras (1992). 2024; 70(7):e20231293.

PMID: 39045925 PMC: 11262315. DOI: 10.1590/1806-9282.20231293.


References
1.
Zhu X, Tian G, Yu B, Yang Y, Wu J . Effects of bisphenol A on ovarian follicular development and female germline stem cells. Arch Toxicol. 2018; 92(4):1581-1591. DOI: 10.1007/s00204-018-2167-2. View

2.
Tarantino G, Valentino R, Di Somma C, DEsposito V, Passaretti F, Pizza G . Bisphenol A in polycystic ovary syndrome and its association with liver-spleen axis. Clin Endocrinol (Oxf). 2012; 78(3):447-53. DOI: 10.1111/j.1365-2265.2012.04500.x. View

3.
Puttabyatappa M, Saadat N, Ramamoorthi Elangovan V, Dou J, Bakulski K, Padmanabhan V . Developmental programming: Impact of prenatal bisphenol-A exposure on liver and muscle transcriptome of female sheep. Toxicol Appl Pharmacol. 2022; 451:116161. PMC: 9618258. DOI: 10.1016/j.taap.2022.116161. View

4.
Muscogiuri G, Barrea L, Laudisio D, Savastano S, Colao A . Obesogenic endocrine disruptors and obesity: myths and truths. Arch Toxicol. 2017; 91(11):3469-3475. DOI: 10.1007/s00204-017-2071-1. View

5.
Zeng X, Xie Y, Liu Y, Long S, Mo Z . Polycystic ovarian syndrome: Correlation between hyperandrogenism, insulin resistance and obesity. Clin Chim Acta. 2019; 502:214-221. DOI: 10.1016/j.cca.2019.11.003. View